Black Diamond Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 1.78 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 102.27M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company’s lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Details
| Name | Black Diamond Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 21 |
| Founded | 2014 |
| Ipo Date | 2020-01-30 |
| Ceo | Mark Velleca |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 19.00 |
| Isin | US09203E1055 |
| Cusip | 09203E105 |
| Cik | 1701541 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Mark A. Velleca M.D., Ph.D. | Chief Executive Officer, President and Chairman |
| Brent Hatzis-Schoch Esq., J.D. | Chief Operating Officer and General Counsel |
| Dr. Sergey Yurasov M.D., Ph.D. | Chief Medical Officer |
| Dr. Elizabeth Buck Ph.D. | Co-Founder and Chief Scientific Officer |
| Erika Jones | Principal Financial Officer, Principal Accounting Officer, SVice President of Finance and Corporate Controller |
| Melanie Morrison | Chief Development Officer |
Contact
| Address | 245 First Street, 18th Floor, Cambridge, Massachusetts 02142, United States |
| Phone | 617 252 0848 |
| Website | https://www.blackdiamondtherapeutics.com |